BlossomHill Therapeutics General Counsel Vincent Paul Liptak buys USD 74,300 of common shares
BLSM•Insider share purchases and option grant
BlossomHill Therapeutics General Counsel Vincent Paul Liptak increased his direct stake to 111,412 common shares via open-market purchases at USD 15.8–16.
He also reported 22,687 common shares held indirectly through the Walter T. Liptak Revocable Trust following a Series B preferred conversion.
Liptak received an employee stock option for 46,561 shares with a USD 16 exercise price.
